Prosecution Insights
Last updated: August 14, 2026

Nippon Chemiphar Co., Ltd.

8 pending office actions • 7 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready

Portfolio Summary

8
Total Pending OAs
4
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (25%)
4
Medium (50%)
2
Easy (25%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (25%)
§112 only1 (12%)
Double-patenting only1 (12%)
Double-patenting + other2 (25%)
Multi-statute (no §101)2 (25%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
88% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
12% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KIFLE, BRUCK 1 79.3% +15.8%
RAHMANI, NILOOFAR 1 77.5% -3.1%
HABTE, KAHSAY 1 85.0% +7.4%
CHANDRAKUMAR, NIZAL S 1 72.7% +18.3%
KASS, BENJAMIN JOSEPH 1 28.9% +61.6%
HEITMEIER, KENDALL NICOLE 1 63.9% +41.7%
HAGHIGHATIAN, MINA 1 45.8% +39.7%
NEAGU, IRINA 1 46.8% +57.4%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18278246 PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF STRESS-RELATED DISORDERS HABTE, KAHSAY 26d

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
17631635 REAGENT CARTRIDGE KASS, BENJAMIN JOSEPH 105d overdue
18694663 MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN RAHMANI, NILOOFAR

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
17631635 REAGENT CARTRIDGE KASS, BENJAMIN JOSEPH 105d overdue
17915361 MEDICAMENT FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE CHANDRAKUMAR, NIZAL S 67d overdue
18817846 P2X4 RECEPTOR ANTAGONIST KIFLE, BRUCK
17626349 METHOD FOR PRODUCING PHENOL DERIVATIVE HEITMEIER, KENDALL NICOLE
17057348 METABOLISM IMPROVING AGENT HAGHIGHATIAN, MINA
16605885 BLOOD PURIFICATION BY ALKALINIZING AGENT NEAGU, IRINA

Top Art Units

Art UnitApps
1691 1
1624 1
1625 1
1798 1
1621 1
1616 1
1629 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18817846 P2X4 RECEPTOR ANTAGONIST KIFLE, BRUCK DP Non-Final OA Pending Aug 28, 2024
18694663 MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN RAHMANI, NILOOFAR 1691 §102§112 Non-Final OA Pending Mar 22, 2024
18278246 PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF STRESS-RELATED DISORDERS HABTE, KAHSAY 1624 §112 Final Rejection 26d Pending Aug 22, 2023
17915361 MEDICAMENT FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE CHANDRAKUMAR, NIZAL S 1625 §103DP Final Rejection 67d overdue Pending Sep 28, 2022
17631635 REAGENT CARTRIDGE KASS, BENJAMIN JOSEPH 1798 §102§103§112Other Final Rejection 105d overdue Pending Jan 31, 2022
17626349 METHOD FOR PRODUCING PHENOL DERIVATIVE HEITMEIER, KENDALL NICOLE 1621 §103 Non-Final OA Pending Jan 11, 2022
17057348 METABOLISM IMPROVING AGENT HAGHIGHATIAN, MINA 1616 §103 Final Rejection Pending Nov 20, 2020
16605885 BLOOD PURIFICATION BY ALKALINIZING AGENT NEAGU, IRINA 1629 §103§112DP Non-Final OA Pending Oct 17, 2019

Managing Nippon Chemiphar Co., Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month